Exelixis Inc experiences decline amid market downturn.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Source: Coinmarketcap
Exelixis Inc's stock fell by 5.00%, crossing down its 5-day SMA as broader market indices also declined, with the Nasdaq-100 down 0.44% and the S&P 500 down 0.46%.
The company is set to host its 2025 R&D Day, focusing on next-generation oncology strategies, which may provide insights into future growth. However, the current market sentiment appears to be overshadowing this upcoming event.
Investors are advised to monitor the market conditions closely, as the overall weakness could impact stock performance despite potential positive developments from the R&D Day.
Analyst Views on EXEL
Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 44.09 USD with a low forecast of 30.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
7 Buy
8 Hold
1 Sell
Moderate Buy
Current: 42.660
Low
30.00
Averages
44.09
High
52.00
Current: 42.660
Low
30.00
Averages
44.09
High
52.00
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
